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Ganglioside GM3 Promotes Carcinoma Cell
Proliferation via Urokinase Plasminogen
Activator-Induced Extracellular Signal-Regulated
Kinase-Independent p70S6 Kinase Signaling
Xiao-Qi Wang1,2, Ping Sun1, Linda Go1, Viola Koti1, Margarita Fliman1 and Amy S. Paller1,2
Overexpression of NeuAca2-3Galb1-4Glcb1-Cer (GM3), a major ganglioside of cutaneous tumor cell
membranes, inhibits ligand-dependent and ligand-independent activation of the epidermal growth factor
(EGF) receptor in normal and neoplastic epithelial cells. This leads to the suppression of Ras/extracellular signal-
regulated kinase (ERK) activation and, in the presence of EGF or fibronectin, inhibits cell proliferation. However,
some tumor cells show increased levels of GM3, and vaccines that target GM3 can inhibit the growth of
neoplastic cells in vivo, especially melanomas. We report that in the presence of urokinase plasminogen
activator (uPA), overexpression of GM3 paradoxically increases the proliferation of carcinoma cells by
augmenting ERK-independent p70S6 kinase activation. Functional blockade of uPA receptor (uPAR) or inhibition
of p70S6 kinase, but not inhibition of Ras/ERK signaling, suppresses this GM3-induced stimulation of cell
proliferation. The ERK-independent activation of p70S6 kinase involves phosphorylation at threonine-389,
threonine-421/serine-424, and serine-411 sites with intermediate phosphatidylinositol 3 kinase and protein
kinase C-z activation. These studies implicate gangliosides as enhancers of uPAR-related signaling and suggest
that the response to GM3 depends on the local concentration of uPA. Therapeutic modalities that target or
supplement gangliosides may require concomitant treatment that suppresses EGFR or uPAR signaling,
respectively, to control neoplastic cell proliferation.
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INTRODUCTION
Gangliosides are membrane acidic glycosphingolipids with at
least one sialic acid moiety linked to their oligosaccharide
chain. The hydrophobic sphingolipid component of ganglio-
sides is anchored within the membrane and the carbohydrate
residues extend into the extracellular environment; thus,
gangliosides are able to interact with other membrane
components or with external agents. Each cell type shows a
distinct pattern of ganglioside content, which is altered by
neoplasia (Mora et al., 1969; Paller et al., 1992; Hakomori,
2001).
Accumulating evidence indicates that gangliosides influ-
ence the activity of several signaling cascades at the
membrane level (Wang et al., 2001a, d, 2002a; Hakomori,
2002). Our previous studies have shown that NeuAca2-
3Galb1-4Glcb1-Cer (GM3), the predominant ganglioside of
neoplastic epithelial cells and melanomas, interacts directly
with EGFR (Wang et al., 2001a, c) and inhibits the dimeriza-
tion of EGFR (Wang et al., 2002a). These interactions inhibit
ligand-dependent activation of the EGFR and its downstream
Ras/extracellular signal-regulated kinase (ERK) signaling
(Wang et al., 2001a, c, 2002a), thus suppressing epithelial
cell proliferation in the presence of epidermal growth factor
(EGF) (Wang et al., 2001a). Overexpression of GM3 is also
able to suppress fibronectin-induced EGFR and Ras/ERK
signaling through inhibition of the crosstalk between EGFR
and the a5b1 integrin (Wang et al., 2003a).
The clearly demonstrated inhibitory effects of GM3 on cell
proliferation of many cell types suggest that functional
depletion of GM3 would stimulate cancer cell growth,
whereas therapies that augment GM3 would lead to
suppression. Although overexpression of ganglioside-specific
sialidase and resultant reduction of GM3 content have been
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seen in some tumors (Kakugawa et al., 2002), low levels of
sialidase and increases in GM3 have been found in highly
metastatic variants of colon adenocarcinomas (Sawada et al.,
2002). Sialidase overexpression in colon adenocarcinoma
cells (Sawada et al., 2002) and melanoma cells (Tokuyama
et al., 1997) retards cell growth and metastasis. In addition,
decreased synthesis of gangliosides by treatment with an
inhibitor of glucosylceramide synthesis inhibits melanoma
tumor growth in a mouse model (Weiss et al., 2003). Most
importantly, gangliosides (such as GM3) have been targeted
increasingly for antitumor vaccine development (Bitton et al.,
2002; Fernandez et al., 2003; Guthmann et al., 2004) and
monoclonal antibody therapy (Irie et al., 2004).
Urokinase plasminogen activator (uPA), a serine protease,
is able to bind to its cell membrane receptor, uPAR, and
thereby initiates signal-transduction events that lead to
remodeling of extracellular matrices, cell migration, invasion,
and proliferation (Ossowski and Aguirre-Ghiso, 2000; Jo
et al., 2003). A wide variety of human tumors, including
melanomas, cutaneous carcinomas, and neoplasms of the
breast, lung, bladder, colon, liver, pleura, pancreas, and
brain, show increased expression and/or activation of uPA
and uPAR (Rosenthal et al., 1998; Blasi and Carmeliet, 2002;
Rofstad et al., 2004). These increases have correlated with
accelerated cell growth and a poor prognosis. The uPAR is
not a transmembrane protein, but is tethered to the cell
surface through a glycosylphosphatidylinositol linkage.
Therefore, the initiation of signal transduction depends upon
its association with transmembrane proteins, including
members of the integrin family (Kugler et al., 2003),
chemotactic receptors (Resnati et al., 2002), and receptor
tyrosine kinases, such as the EGFR (Liu et al., 2002). Although
the association of uPAR with these proteins is well
documented, little is known about the underlying molecular
mechanisms and factors that modulate the uPAR signaling
response.
Recent studies have demonstrated that uPAR and gang-
lioside GM3 cosegregate in membrane rafts (Gomez-Mouton
et al., 2001), suggesting that GM3 may participate in the
regulation of uPAR signaling. We examined the effect of GM3
elevation on uPAR signaling-induced carcinoma cell prolif-
eration. Surprisingly, we found that GM3 overexpression in
the presence of uPA augments, rather than suppresses, uPAR
signaling-induced cell proliferation. The mechanism of this
novel effect of GM3 appears to involve ERK-independent
activation of the 70 kDa ribosomal S6 (p70S6) kinase, a
serine/threonine protein kinase that is known to stimulate cell
proliferation and survival (Dufner and Thomas, 1999).
Activation of protein kinase C (PKC)-z and phosphatidyl-
inositol 3 kinase (PI3K) (Weng et al., 1995; Pullen and
Thomas, 1997; Romanelli et al., 1999) is required for the
uPA-induced stimulation of p70S6 kinase by GM3.
RESULTS
GM3 overexpression stimulates carcinoma cell proliferation
Previous work from our laboratory has demonstrated that
elevated expression of GM3 inhibits SCC12 cell proliferation
in response to EGF (Wang et al., 2001a) or fibronectin (Wang
et al., 2003a). In contrast, increased GM3 levels make these
cells much more responsive to the stimulation by uPA
(Figure 1). After 24 hours of treatment with uPA, augment-
ation of GM3 by genetic or biochemical manipulation
increases the expression of proliferating cell nuclear antigen
(PCNA), a marker of proliferating cells (Figure 1a, top row,
lanes 3 and 6) and BrdU incorporation (Figure 1b, bars 3 and
5) relative to control cells (Figure 1a, top row, lanes 1, 2, 4,
and 5; Figure 1b, bars 1, 2, and 4). In the presence of either
EGF (Figure 1a, middle row) or fibronectin (Figure 1a, bottom
row), GM3 overexpression diminishes PCNA expression. In
the absence of supplemental uPA, EGF, or fibronectin, PCNA
expression and BrdU incorporation are not detected (not
shown). The expression of GM3 after these manipu-
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Figure 1. GM3 overexpression stimulates uPA-induced PCNA expression
and BrdU incorporation. GM3 expression in SCC12 cells was increased by
treatment with either antisense oligomers to block the synthesis of down-
stream gangliosides of GM3 (Wang et al., 2002a) or pharmacological addition
of purified GM3 (Wang et al., 2001a). (a) After starvation of serum and growth
factors, cells were stimulated with 10 nM uPA (top row), 100 ng/ml EGF
(middle row), or 10 mg/ml fibronectin (bottom row) for 24 hours. Eight
microgram of total protein from the whole-cell lysate was applied to a 12%
SDS-PAGE mini-gel and probed with anti-PCNA antibody; lanes 1 and 4,
parental SCC12 cells; lane 2, cells treated with sense oligomers to serve as
a control (sense); lane 3, cells treated with antisense oligomers to block the
GM3 metabolism (antisense); lane 5, cells treated with vehicle, DMSO, as a
control for GM3-treated cells (vehicle); and lane 6, pharmacological addition
of GM3 (GM3). (b) BrdU incorporation was measured in cells prepared as
indicated. The figure represents the means7SD of studies from three different
experiments. The changes in GM3 expression are shown in parentheses;
bar 1, parental SCC12 cells; bar 2, cells treated with sense oligomers to serve
as a control (sense); bar 3, cells treated with antisense oligomers to block
the GM3 metabolism (antisense); bar 4, cells treated with vehicle, DMSO,
as a control for GM3-treated cells (vehicle); and bar 5, pharmacological
addition of GM3 (GM3). The expression of GM3 after genetic manipulation
(increased 2.35-fold, bar 3) or pharmacological addition (increased 1.98-fold,
bar 5) was detected by (c) ganglioside ELISA (Wang et al., 2002b) and
(d) TLC immunostaining (Wang et al., 2002a); Sta¼ ganglioside standard
(*Po0.05; **Po0.01).
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lations was increased 2- to 2.5-fold as detected by ganglio-
side ELISA (Figure 1c; Wang et al., 2002b) and by thin-layer
chromatography (TLC) immunostaining (Figure 1d; Wang et al.,
2002a,b).
GM3 overexpression triggers uPA-induced p70S6 kinase
activation by an ERK-independent pathway
The decreased SCC12 cell proliferation that results from GM3
overexpression in the presence of EGF or fibronectin
correlates with the impaired activation of ERK (Wang et al.,
2001a, 2003a, b). To address the requirement for ERK
activation in uPA-induced cell proliferation when GM3
expression is altered, ERK phosphorylation and activity were
assessed. As with cells stimulated with EGF or fibronectin,
uPA fails to induce either ERK phosphorylation (Figure 2a,
middle row) or activation (Figure 2a, bottom row) when GM3
is elevated (lane 3). To screen for the potential uPA-induced
signaling pathways that might be impacted by GM3 over-
expression, tyrosine and serine/threonine phosphorylation of
the total protein from the whole-cell lysate was assessed.
GM3 overexpression results in decreased tyrosine phosphor-
ylation of a band at approximately 170 kDa (presumed to be
EGFR), but increases serine/threonine phosphorylation at a
band of approximately 70 kDa (data not shown). We
hypothesized that this 70 kDa band represented increased
serine/threonine phosphorylation of p70S6 kinase, a kinase
known to induce cell survival and cell proliferation (Hirata
and Kiuchi, 2003).
Kinase assays of uPA-treated cells with increased GM3
expression show significant increases in p70S6 kinase activity
(Figure 2b, bars 4 and 7), in comparison with controls (Figure
2b, bars 1, 3, and 6). Blockade of ERK activity does not affect
the increased p70S6 kinase activity in cells with over-
expressed GM3 (Figure 2b, bars 5 and 8).
Serine and threonine phosphorylation of the p70S6 kinase
is increased by GM3 overexpression, even in the presence of
blockade of ERK signaling by PD98059 (Figure 2c, lane 3,
middle and bottom rows), when compared to control cells
(parental SCC12 cells and sense oligomer-treated cells)
(Figure 2c, lanes 1 and 2).
In the absence of uPA, no ERK phosphorylation and
activity (Figure 2a, lanes 4–6, middle and bottom rows),
p70S6 kinase activity (Figure 2b, bars 9–16), or p70S6 kinase
phosphorylation (Figure 2c, lanes 4–6, middle and bottom
rows) is detected. Modulation of GM3 expression does not
affect either ERK or p70S6 kinase expression (not shown).
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Figure 2. Overexpression of GM3 in the presence of uPA inhibits ERK activation, but stimulates ERK-independent p70S6 kinase activation. Cells were
prepared as indicated in Figure 1a. (a) ERK and (b, c) p70S6 kinase were immunoprecipitated from the whole-cell lysate as described in Materials and Methods.
Equal loading of the immunoprecipitated kinases was confirmed by immunoblotting with either (a, top row) anti-ERK antibody or (c, top row) anti-p70S6 kinase
antibody . (a) Using immunoprecipitated ERK, the effect of GM3 on the phosphorylation of ERK was detected with anti-phospho-ERK antibody (middle row). The
activity of this kinase was measured using immunoprecipitated ERK to incubate with its substrate in the presence of [g-32P]ATP as described in Materials and
Methods (bottom row). Lane 1, parental SCC12 cells; lane 2, cells treated with sense oligomers to serve as a control (sense); lane 3, cells treated with antisense
oligomers to block the GM3 metabolism (antisense); and lanes 4–6, cells are same as lane 1–3, but without uPA stimulation. (b) Using immunoprecipitated
p70S6 kinase, the effect of GM3 overexpression on the activity of p70S6 kinase was detected in the presence or absence of PD98059, an ERK inhibitor; bars 1–2,
parental SCC12 cells treated without or with PD98059; bar 3, sense oligomer-treated cells (sense); bars 4–5, antisense oligomer-treated cells in the absence or
presence of PD98059 (antisense); bar 6, vehicle DMSO-treated cells (DMSO); bars 7–8, cells with pharmacological addition of GM3 in the absence or presence
of PD98059 (GM3); and bars 9–16, cells are same as bar 1–8 but without uPA stimulation. (c) The phosphorylation of p70S6 kinase was detected using anti-
phosphoserine (middle row) or anti-phosphothreonine antibodies (bottom row); lane 1, parental SCC12 cells; lane 2, cells treated with sense oligomers to serve
as a control (sense); lane 3, cells treated with antisense oligomers to block the GM3 metabolism (antisense); and lanes 4–6, cells are same as lane 1–3, but
without uPA stimulation. Data from the p70S6 kinase assay are presented as fold increase from parental SCC12 cell controls in the absence of inhibitors (n¼ 3,
means7SD). The figures are representative of all cell lines studied (**Po0.01; ***Po0.001). P-values reflect the comparison of cells with increased GM3 with
their respective control cells; #Po0.05 of SCC12 cells with ERK inhibition (solid bar) versus no inhibition (open bar).
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To further examine the contribution of ERK signaling and
p70S6 kinase signaling to uPA-stimulated cell proliferation in
the presence of elevated GM3, we also employed GM3-
depleted cells. GM3 was depleted by treatment of cells with
threo-1-phenyl-2-hexadecanoyl-amino-3-pyrrolidinopropan-
1-ol HCl (PPPP) (a chemical reagent to block the synthesis of
GM3 precursor) or by stable transfection of a human
ganglioside-specific plasma membrane sialidase (to cleave
the sialic acid residue from GM3 and render GM3 non-
functional). The depletion of GM3 in PPPP-treated cells and
sialidase-overexpressing cells (SSIA) was confirmed by TLC
immunostaining (Figure 3a). Ceramide, a bioactive molecule,
is a precursor of GM3 and is known to affect cell signaling. To
clarify the effect of GM3 modulation on ceramide expression,
TLC immunostaining was performed. Modulation of GM3
expression by treatment of cells with PPPP does not lead to
the accumulation of ceramide (Figure 3b) (Abe et al., 1995).
In the presence of elevated GM3, cells were treated with
either PD98059, an inhibitor of ERK, or rapamycin, an
inhibitor of the mammalian target of rapamycin (mTOR), and
p70S6 kinase, which is the downstream signaling molecule of
mTOR. Inhibition of p70S6 kinase activity (Figure 3c, lane 7),
but not ERK activity (Figure 3c, lane 6), eradicates the uPA-
induced PCNA expression triggered by increased GM3. In
contrast, uPA-induced PCNA expression in control cells (cells
without increased GM3) could be prevented by inhibiting
ERK activity (Figure 3c, lane 2), but not p70S6 kinase activity
(Figure 3c, lane 3). Activity assays showed that rapamycin
(Figure 3d, bar 7), but not PD98059 (Figure 3d, bar 6),
interferes with the p70S6 kinase activity triggered by GM3
overexpression in comparison with cells treated without
inhibitor (Figure 3d, bar 5) (Po0.001). This result indicates
that uPA-induced cell proliferation in cells with elevated
GM3 depends on p70S6 kinase activation, not ERK signaling.
Depletion of GM3 also significantly increases the activity
of p70S6 kinase (Figure 3d, bars 9 and 13). Treatment with
rapamycin to block p70S6 kinase activation (Figure 3d, bars
11 and 15) or with PD98059 to block ERK signaling (Figure
3d, bars 10 and 14) eliminates the increase in p70S6 kinase
activity. However, only blockade of ERK signaling eradicates
the expression of PCNA in cells with depleted gangliosides
(Figure 3c, lanes 10 and 14).
Given the contribution of ERK signaling to the increased
p70S6 kinase activity of GM3 depletion (Figure 3d, bars 10
and 14) and in an effort to focus on cell function modulated
by ERK-independent p70S6 kinase activation, all additional
studies were performed in the presence of both uPA and the
inhibitor of ERK, PD98059.
The uPA-stimulated p70S6 kinase activation and PCNA expres-
sion in the presence of elevated GM3 require uPAR signaling
Neutralization of the uPAR bioactivity with anti-human uPAR
antibody (R&D Systems Inc., Minneapolis, MN) blocks ERK-
independent PCNA expression in cells with elevated GM3
(Figure 4a, lane 9) in comparison with untreated GM3-
overexpressing cells (Figure 4a, lanes 7 and 8). Anti-uPAR
antibody also profoundly inhibits p70S6 kinase activation
triggered by elevated GM3 in the presence of uPA and
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Figure 3. Rapamycin, but not PD98059, blocks the uPA stimulation of PCNA
expression in cells with elevated GM3. (a) GM3 was depleted either by stable
transfection of cells with a human plasma ganglioside-specific sialidase (SSIA)
to render GM3 non-functional or by treatment of cells with 2 mM PPPP for
5 days to block the synthesis of GM3 precursor, lactosylceramide.
(b) Treatment with PPPP did not affect ceramide expression. Gangliosides and
ceramide were detected by TLC immunostaining (Wang et al., 2002a). Cells
with or without GM3 modulation were treated with 100mM of PD98059, a
specific inhibitor of ERK, or 100 ng/ml of rapamycin (Chung et al., 1992), an
inhibitor to mTOR and p70S6 kinase (a downstream signaling molecule of
mTOR), for 12 hours and then stimulated with uPA for 10 minutes. (c) Eight
microgram of total protein from the whole-cell lysates was applied to a 12%
SDS-PAGE mini-gel and probed with anti-PCNA antibody; lanes 1–3, parental
SCC12 cells treated with or without PD98059 or rapamycin; lane 4, sense
oligomer-treated cells (sense); lanes 5–7, antisense oligomer-treated cells in
the absence of presence of either PD98059 or rapamycin (antisense); lane 8,
pcDNA-transfected mock control for SSIA cells (pcDNA); lanes 9–11, SSIA
cells treated without or with PD98059 or rapamycin; lane 12, vehicle DMSO-
treated cells (vehicle); and lanes 13–15, cells treated with PPPP in the absence
or presence of PD98059 or rapamycin. p70S6 kinase was immunoprecipi-
tated from the whole-cell lysates and incubated with S6 kinase peptide in the
presence of [g-32P]ATP as indicated in Materials and Methods. (d) The activity
of p70S6 kinase (n¼ 3, mean7SD) is presented as fold increase above
parental SCC12 cells treated without inhibitors ; bars 1–3, parental SCC12
cells treated with or without PD98059 or rapamycin; bar 4, sense oligomer-
treated cells (sense); bars 5–7, antisense oligomer-treated cells in the absence
of presence of either PD98059 or rapamycin (antisense); bar 8, pcDNA-
transfected mock control for SSIA cells; bars 9–11, SSIA cells treated without
or with PD98059 or rapamycin; bar 12, vehicle DMSO-treated cells (vehicle);
and bars 13–15, cells treated with PPPP in the absence or presence of
PD98059 or rapamycin. The figures are representative of all cell lines studied
(*Po 0.05; **Po0.01; ***Po0.001). P-values compare the hatched or solid
bars with the open bars. Sta¼ ganglioside standard; pcDNA¼ vector control
for SSIA; and SSIA¼ cells stably transfected with human ganglioside-specific
plasma membrane sialidase.
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PD98059 (Figure 4b, bar 9 versus 8, Po0.001). Neither EGF
nor fibronectin affects the activation of p70S6 kinase in cells
with increased GM3 (Figure 4c, solid bars). These data
indicate that p70S6 kinase activation triggered by GM3
depends on uPAR signaling.
Activation of uPAR in cells that overexpress GM3 induces
ERK-independent phosphorylation of p70S6 kinase at threo-
nine 421/serine 424, threonine 389, and serine 411 sites
(Figure 5, lane 3 of the second, third and bottom rows) in
comparison with control cells (lanes 1 and 2). GM3 depletion
prevents p70S6 kinase phosphorylation at all these sites when
ERK activity was inhibited (Figure 5, lanes 6, 7, and 10 of the
second, third and bottom rows) compared with controls
(lanes 4, 5, 8, and 9).
Activation of PI3K or PKC-f phosphorylates ERK-independent
p70S6 kinase at specific sites and enhances p70S6 kinase
activity in cells with elevated GM3
Several signaling pathways are known to modulate the
activation of p70S6 kinase, including PI3K, mTOR, and
PKC signaling (Chung et al., 1992, 1994; Pullen and Thomas,
1997; Romanelli et al., 1999). To address the possible role of
PKC and PI3K signaling in the activation of p70S6 kinase by
uPAR signaling in the presence of elevated GM3, cells were
treated with inhibitors of PKC or PI3K signaling. We have
previously found that PKC-a, PKC-d, PKC-Z, PKC-j, and PKC-
z are expressed by SCC12 cells (unpublished data). SCC12
cells were treated with inhibitors directed against PKC-a,
PKC-d, PKC-Z, PKC-j, or PKC-z, and the effects of these
inhibitors on p70S6 kinase activation were observed (data not
shown). Of these, only PKC-z inhibitor decreases p70S6
kinase phosphorylation and activity (Figure 6a and b), as has
previously been demonstrated in human embryonic kidney
cells (Romanelli et al., 1999). Treatment of SCC12 cells with
a synthetic pseudopeptide of PKC-z (SIYRRGARRWRKL,
Calbiochem) (Laudanna et al., 1998) dramatically inhibits
PKC-z activity (Figure 6b, inset) and, in the presence of
supplemental uPA and elevated GM3, dramatically reduces
p70S6 kinase phosphorylation at both the threonine 421/
serine 424 and serine 411 sites (Figure 6a, lane 6 of the top
and middle rows). Blockade of PI3K activity with either 20 mM
of LY294002 or 100 nM of wortmannin significantly inhibits
the p70S6 kinase phosphorylation at both threonine 421/
serine 424 and threonine 389 sites (Figure 6a, lanes 3 and 4
of the top and bottom rows). The decrease in p70S6 kinase
phosphorylation at these specific sites by PI3K and PKC-z
inhibitors correlates with the reduction in p70S6 kinase
activity (Figure 6b). Inhibition of either PI3K (Figure 6b, bar 4)
or PKC-z (Figure 6b, bar 5) alone leads to partial inhibition of
p70S6 kinase activation, whereas inhibition of both PI3K and
PKC-z concurrently reduces p70S6 kinase activities to base-
line levels (Figure 6b, bar 6) in comparison with untreated
GM3-overexpressing cells (bar 3), parental SCC12 cells (bar
1), and sense oligomer-treated control cells (bar 2).
a
SCC12
1 2 3 4 5 6 7 8 9
Antisense
(GM3↑)
Sense
PD98059
Anti-uPAR
uPA
–
–
+
+
+
+
+
+ + +
+ +
+
+ + + +
+
++
–
–
– –
–
– –
-PCNA
SCC12
1
0
2
3
4
5
1
2
3
4
5
1 2 3 4 5 6 7 8 9
Antisense (GM3↑)
SCC12 Antisense
(GM3↑)
Sense
Sense
PD98059
Anti-uPAR
uPA
uPA EGF Fibronectin
p7
0S
6 
kin
as
e
a
ct
iv
ity
 (fo
ld
)
p7
0S
6 
kin
as
e
a
ct
iv
ity
 (fo
ld
) ***
+ +
+ +
+
+
+
+
+++
+
– – –
+
+
++
+
––
–
+
–
––
b c
***
Figure 4. The stimulation of p70S6 kinase activity by GM3 overexpression
requires uPAR signaling. GM3 expression in SCC12 cells was endogenously
modulated as described in Materials and Methods. The expression of GM3
was detected by ganglioside ELISA or TLC immunostaining as shown in
Figures 1 and 3. (a) Starved cells were incubated in DMEM/F12 medium
containing 0.6% BSA with or without 1 mg/ml of anti-uPAR neutralization
antibody in the presence or absence of PD98059 for 24 hours before the
stimulation with uPA. After stimulation with 10 nM uPA, cells were lysed, and
(a) PCNA expression or (b) p70S6 kinase activity was detected as described;
lane or bar 1, parental control cells (SCC12); lane or bar 2, PD98059-treated
parental control cells; lane or bar 3, PD98059- and anti-uPAR antibody-
treated parental control cells; lane or bar 4, negative control cells (sense); lane
or bar 5, PD98059-treated negative control cells; lane or bar 6, PD98059- and
anti-uPAR antibody-treated negative control cells; lane or bar 7, cells with
increased GM3 (antisense); lane or bar 8, PD98059-treated GM3-over-
expressing cells; and lane or bar 9, PD98059- and anti-uPAR antibody-treated
GM3-overexpressing cells. (c) Starved cells were stimulated with 10 nM uPA,
100 ng/ml EGF or 10mg/ml fibronectin (Wang et al., 2003a) for 10 minutes.
p70S6 kinase was immunoprecipitated from cells and the activity of p70S6
kinase was measured as described above (***Po0.001).
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Figure 5. uPA stimulates ERK-independent p70S6 kinase phosphorylation in
cells with elevated GM3, but not in cells without GM3. Cells prepared as
described in Figure 3. To study ERK-independent p70S6 kinase activation,
cells were treated with 100 mM of PD98059, a specific inhibitor of ERK, for
12 hours, and then stimulated with uPA for 10 minutes. p70S6 kinase was
immunoprecipitated from cells as described in Materials and Methods. An
aliquot of the immunoprecipitated p70S6 kinase was applied onto a 10%
SDS-PAGE mini-gel and probed with antibody directed against the p70S6
kinase (top row), p70S6 kinase phosphothreonine 421/serine 424 (second
row), p70S6 kinase phosphothreonine 389 (third row), or p70S6 kinase
phosphoserine 411 site (bottom row). Lanes 1, 4, and 8, parental control
cells (SCC12); lane 2, sense oligomer-treated control cells (sense); lane 3,
GM3-overexpressing cells (antisense); lane 5, pcDNA-transfected mock
control cells; lanes 6–7, sialidase-overexpressing cells with depleted GM3
(SSIA3 and SSIA 6 clones); lane 9, vehicle DMSO-treated cells (vehicle);
and lane 10, PPPP-treated cells with depleted GM3.
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The effect of GM3 overexpression on uPA-induced
activation of PI3K and PKC-z was analyzed by in vitro kinase
activity assays (Wang et al., 2002b). uPA stimulates the
activation of both PI3K (Figure 7a, lanes 3 and 5 of top row)
and PKC-z (Figure 7b, solid bars), independent of ERK
signaling. Alteration in GM3 expression does not affect the
expression of PI3K (Figure 7a, bottom row) or PKC-z (not
shown).
DISCUSSION
In this report, we have shown that increased levels of
ganglioside GM3 in human squamous carcinoma cells
activate uPA-induced p70S6 kinase signaling and thereby
stimulate carcinoma cell proliferation by an ERK-indepen-
dent signaling pathway. p70S6 kinase is a ubiquitously
expressed serine/threonine protein kinase that phosphorylates
the 40S ribosomal protein S6 in response to mitogen
stimulation (Dufner and Thomas, 1999). Inactivation of
p70S6 kinase is known to suppress cell growth and survival
(Lane et al., 1993; Pullen and Thomas, 1997). The activation
of p70S6 kinase and stimulation of cell proliferation by
elevated GM3 specifically requires the presence of uPA, an
activator that is expressed at higher levels in many cancer
cells and the activity of which correlates inversely with
prognosis. This novel stimulatory effect of GM3 contrasts
sharply with the previously demonstrated inhibitory effects of
GM3 on squamous carcinoma cell proliferation when the
same cells are grown without supplemental uPA, but in the
presence of EGF or on a fibronectin matrix (Wang et al.,
2001a, 2003a). Activation of p70S6 kinase signaling may be
either independent of (Ming et al., 1994) or dependent on
(Eguchi et al., 1999) Ras/ERK signaling. Here, we demonstrate
that GM3 overexpression augments uPA-induced ERK-inde-
pendent p70S6 kinase activation, whereas GM3 depletion
promotes ERK-dependent p70S6 kinase activation. Further-
more, inhibition of ERK-independent p70S6 kinase, but not of
ERK or ERK-dependent p70S6 kinase, eliminates the prolif-
erative effect caused by GM3 overexpression. This implicates
GM3 as a membrane adaptor molecule that modulates the
effect of ERK signaling on p70S6 kinase activation as well as
the effect of p70S6 kinase on cell proliferation.
The binding of uPA to uPAR is well known to cause
proteolysis. In addition, binding of uPA to its receptor can
activate ERK signaling (Aguirre-Ghiso et al., 2001). This leads
to constitutive activation of focal adhesion kinase, PI3K, PKC,
EGFR, and mitogen-activated protein kinase and results in
uPA/uPAR-dependent tumor growth (Ossowski and Aguirre-
Ghiso, 2000; Aguirre-Ghiso et al., 2001). For the first time,
we have shown that uPAR activation can also trigger p70S6
kinase activation, either through ERK or ERK-independent
pathways, depending on the expression of ganglioside GM3.
In the presence of elevated GM3, the stimulatory effects of
GM3 on uPA-induced ERK-independent activation of p70S6
kinase signaling and cell proliferation overcome the inhibi-
tory effects of GM3 on ERK signaling-modulated cell
proliferation.
Several signaling molecules modulate the activation of
p70S6 kinase, among them PI3K, mTOR, and PKC (Chung
et al., 1992, 1994; Pullen and Thomas, 1997; Romanelli
et al., 1999). The regulation of p70S6 kinase activation is
complex and requires phosphorylation at multiple sites for
full activation. Our studies also demonstrate that ERK-
independent activation of S6 kinase by uPAR signaling
involves phosphorylation at threonine 421/serine 424,
threonine 389, and serine 411 sites, sites that require
activation of PI3K or PKC-z for phosphorylation (Eguchi
et al., 1999; Romanelli et al., 1999; Zhang et al., 2001).
These findings implicate PI3K and PKC-z, both known
activators of p70S6 kinase, as intermediates in the signaling
pathway by which overexpression of GM3 triggers p70S6
kinase activation in the presence of uPA.
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Figure 6. PKC-f and PI3K signaling pathways mediate uPA-induced ERK-
independent p70S6 kinase activation and phosphorylation at specific sites in
the presence of elevated GM3. (a) Cells with elevated GM3 prepared as
described in Figure 1 were treated with 100 mM of PD98059, a specific
inhibitor of ERK, in the presence or absence of 20 mM of LY294002 or 100 nM
of wortmannin (both inhibitors of PI3K), 50mM of the pseudopeptide inhibitor
of PKC-z, or both LY294002 (20 mM) and pseudopeptide inhibitor of PKC-z
(50mM). The vehicle of the PI3K inhibitors or PKC-z pseudopeptide was
applied as a control. The phosphorylation of p70S6 kinase at different sites
was detected as described in Figure 5; lane 1, GM3-overexpressing cells; lane
2, cells treated with DMSO to serve as a vehicle control for PI3K inhibitor-
treated cells; lane 3, cells treated with PI3K inhibitor, LY294002; lane 4, cells
treated with PI3K inhibitor, wortmannin; lane 5, cells treated with PBS as a
vehicle control for cells treated with PKCz pseudopeptide inhibitor; and lane
6, cells treated with PKCz pseudopeptide inhibitor. (b) Cells were prepared as
indicated in Figure 6a. The effect of PI3K and PKC-z on p70S6 kinase activity
was measured as described in Materials and Methods. The activity of p70S6
kinase is presented as fold increase above parental SCC12 cells treated
without inhibitors (n¼ 3, mean7SD) The effect of pseudopeptide inhibitor on
uPA-stimulated PKC-z activity in normal SCC12 cells was detected by in vitro
kinase activity assay as described in Materials and Methods and shown as the
inset in 6(b) (*Po0.05; **Po0.01; ***Po0.001); bar 1, parental control cells
(SCC12); bar 2, sense oligomer-treated control cells (sense); and bars 3–6,
GM3-overexpressing cells (antisense) treated without (bar 3) or with PI3K
inhibitor, LY294002 (bar 4), PKCz pseudopeptide inhibitor (bar 5), or both
inhibitors (bar 6).
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The mechanism by which GM3 associates with uPAR at
the membrane level to trigger S6 kinase activation is unclear.
Gomez-Mouton et al. (2001) have shown the co-segregation
of GM3 and uPAR in membrane lipid rafts, sites at which
signaling molecules are thought to aggregate to enable
communication. We have recently shown that GM3 regulates
the ability of uPAR and integrin a5b1 to associate with EGFR
and affect EGFR signaling (Wang et al., 2005). GM3 does not
affect either the binding of uPA with uPAR or the expression
of uPAR (unpublished data). Given the known association of
uPAR, integrins (a5b1 and avb3), and caveolin-1 in raft areas
(Stahl and Mueller, 1995; Wei et al., 1996, 2005; Hapke
et al., 2001; Wang et al., 2005), and the known ability of
GM3 to associate with caveolin-1 (Wang et al., 2002a),
integrins (Wang et al., 2005) and uPAR (unpublished data),
we propose that GM3 modulates uPAR signaling and
activates p70S6 kinase through this lipid raft-based complex
(see Figure 8 for hypothetical model).
The increased expression of gangliosides, uPA, and uPA
receptors in a variety of malignant tumors may provide
a milieu in which gangliosides stimulate tumor cell prolifera-
tion through augmentation of uPAR signaling. GM3, a
predominant ganglioside of neoplastic epithelial cells and
melanocytes, has been targeted as a candidate for antigan-
glioside therapeutic regimens and is also considered as a
potential inhibitor of tumor cell growth (Watanabe et al.,
2002). Our data suggest that the ability of gangliosides to
regulate cell behavior depends greatly on the tumor cell
milieu and the presence of growth factors and matrix
components, including uPA. These studies provide a ratio-
nale for the treatment of malignancies concurrently with
either agents that target both GM3 and EGFR signaling
pathways, or that increase GM3 membrane content and
inhibit uPAR signaling, depending on the tumor cell response
to GM3.
MATERIALS AND METHODS
Cells
The human squamous carcinoma cell, SCC12F2 cell line (SCC12)
(courtesy of Dr James Rheinwald, Boston, MA), was chosen as the
model cell, given the previously shown inhibitory effect of GM3 on
proliferation in the presence of EGF or fibronectin (Wang et al.,
2001c, 2002a, 2003a) and low basal expression of uPA in this cell
line. SCC12 cells were maintained in Dulbecco’s modified eagle’s
medium/F12 (DMEM/F12, 1:1, (v/v)) medium (Invitrogen, Carlsbad,
CA) supplemented with 10% heat-inactivated fetal bovine serum
without antibiotics in 5% CO2 at 371C.
Ganglioside expression modulation
Expression of ganglioside by SCC12 cells was modulated by (a)
pharmacological addition of purified GM3 (Sigma, St Louis, MO)
into cell culture medium as described (Wang et al., 2001a, b, d) to
increase cell membrane GM3 content; (b) antisense oligodeoxy-
nucleotide treatment to overexpress ganglioside GM3 by blockade of
the synthesis of downstream gangliosides of GM3 (Wang et al.,
2002a, 2003a, b); (c) stable transfection of SCC12 cells with a human
plasma membrane, ganglioside-specific sialidase cDNA (GenBank
accession number AB008185, courtesy of Dr T. Miyagi, Tokyo,
Japan), (Wada et al., 1999) to cleave the sialic acid residue from
GM3 and render it non-functional (Wang et al., 2001a; Sun et al.,
2002); and (d) treatment of cells with 2 mM PPPP (Matreya, Pleasant
Gap, PA), which prevents the formation of glucosylceramide, the
GM3 precursor (Wang et al., 2002a, 2003b).
Immunoblotting
Immunoblotting was carried out as described (Wang et al., 2001b, d)
using immunoprecipitated protein or total protein from the whole-
cell lysates and an enhanced chemiluminescence detection system
(Perkin-Elmer Life Sciences, Wellesley, MA). Whole-cell lysate was
acquired using cells prepared as described (Wang et al., 2002a). In
brief, cells with or without modulation of ganglioside expression
were treated with or without inhibitors of ERK (100 mM of PD98059,
Calbiochem, San Diego, CA), p70S6 kinase (100 ng/ml of rapa-
mycin, Sigma), PI3K (20 mM of LY294002, Calbiochem, or 100 nM of
wortmannin, Sigma) or PKC-z (50 mM of pseudopeptide, SIYRR-
GARRWRKL (positions 113–125), Calbiochem) (Laudanna et al.,
1998) for 24 hours. Cells were then starved of both serum and growth
factors overnight in the presence or absence of inhibitors, and
-
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Figure 7. uPA activates PI3K and PKC-f in the presence of ERK inhibitors.
Cells prepared as described in Figure 1a were treated with the PD98059,
an ERK inhibitor, and 10 nM uPA was added for 10 minutes. (a) The PI3K
activity was measured using the immunoprecipitated p85 subunit of PI3K.
After incubation of the immunoprecipitated PI3K with its substrate,
phosphatidylinositol, in the presence of [g-32P]ATP, PI3K activity was
detected as described (Wang et al., 2002b); lane 1, parental control (SCC12);
lane 2, DMSO-treated vehicle control (vehicle); lane 3, pharmacological
addition of GM3 (GM3); lane 4, sense oligomer-treated control (sense); and
lane 5, antisense oligomer-treated cells with increased GM3 (antisense).
(b) The activity of PKC-z was analyzed using immunoprecipitated PKC-z
in the presence of both MBP and [g-32P]ATP as described in Materials and
Methods (***Po0.001); bar 1, parental control (SCC12); bar 2, DMSO-treated
vehicle control (vehicle); bar 3, pharmacological addition of GM3 (GM3);
bar 4, sense oligomer-treated control (sense); and bar 5, antisense
oligomer-treated cells with increased GM3 (antisense).
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stimulated with 10 nM uPA (Calbiochem) for 10 minutes to 24 hours
before lysis. For immunoblotting, an aliquot of immunoprecipitates
or 8–60mg of total protein from the whole-cell lysate was treated
with denatured or undenatured Laemmli buffer as indicated in the
figure legends, and loaded onto SDS-PAGE mini-gels. After transfer
to polyvinylidene difluoride or nitrocellulose membranes, the
separated proteins were detected by immunoblotting with antibodies
directed against the PCNA, p70S6 kinase, phospho-p70S6 kinase at
Thr-421/Ser-424, Thr-389, or Ser-411sites (Santa Cruz Biotech, Inc.,
Santa Cruz, CA), phosphoserine, phosphothreonine (CalBiochem),
p42/p44 mitogen-activated protein kinase (ERK1/2), and phospho-
ERK1/2 (BioSource, Camarillo, CA). Blots using total protein were
reprobed as described previously (Wang et al., 2001b) with anti-
actin antibody (Santa Cruz Biotechnology Inc.) to confirm equal
loading. All blots were repeated in at least three different
experiments. When using the immunoprecipitated protein for
blotting, the 150 kDa undenatured whole IgG band, 55 kDa
denatured heavy chain of the IgG band, and, when detectable, the
25 kDa denatured light chain of the IgG band were cut from the blots
for figure presentation.
Immunoprecipitation
Cells were prepared as indicated above and stimulated with or
without 10 nM uPA for 10 minutes after starvation of serum and EGF
for overnight. Cells were harvested and lysed in cold immuno-
precipitation buffer as described previously (Wang et al., 2001b, d).
Total protein (1 mg) from the cell lysates was mixed with 5 mg of
polyclonal antibody directed against p70S6 kinase (Santa Cruz
Biotechnology Inc), ERK1/2, p85 subunit of PI3K, or PKC-z and the
total reaction volume was adjusted to 1 ml in the immunoprecipita-
tion buffer. After incubation with the antibodies for 2 hours at 41C,
protein A: agarose was added for an additional 30 minutes at 41C
(Wang et al., 2001b).
Kinase activity assays
Kinase activity was assessed using immunoprecipitated p70S6
kinase, ERK1/2, PI3K, or PKC-z (Eguchi et al., 1999; Wang et al.,
2001a). An S6 kinase peptide (RRRLSSLRA, Santa Cruz Biotech Inc)
was selected as a substrate for measuring p70S6 kinase activity.
Myelin basic protein (Sigma) was selected as a substrate for
determining ERK activity and PKC-z activity, and phosphatidylino-
sitol (Sigma) was chosen as a substrate for PI3K activity analysis.
p70S6 kinase, ERK1/2, PI3K, or PKC-z was immunoprecipitated from
the whole-cell lysate with polyclonal antibody directed against
p70S6 kinase, ERK1/2, p85 subunit of PI3K, or PKC-z, respectively,
as described above. Whole-cell lysates were prepared from
stimulated starved cells with 10 nM of uPA for 10 minutes. One-third
of the immunoprecipitate was boiled in Laemmli buffer and applied
to a 12 or 10% SDS-PAGE mini-gel to confirm the purity and equal
precipitation of proteins by probing the membrane with anti-p70S6
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Figure 8. Proposed mechanism of GM3-triggered uPAR activation and cell proliferation. uPAR associates with integrin a5b1 (Wang et al., 2005) to
cross-activate EGFR signaling (Wang et al., 2003a) in the presence of uPA. uPA is able to stimulate cell proliferation via either ERK-dependent or ERK-
independent pathways. Cells show increased proliferation in the presence of uPA whether GM3 is increased or decreased. However, the underlying mechanism
of increasing cell proliferation is different in the presence of increased GM3 versus the absence of GM3. In contrast to (a) quiescent control cells, cells that
(b) overexpress GM3 show activation of PI3K and PKC-z, increased p70S6 kinase activity, and cell proliferation, despite suppression of ERK signaling.
Cells in which GM3 is (c) depleted show activation of ERK signaling, leading to increased cell proliferation that is independent of p70S6 kinase activation.
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kinase, anti-ERK1/2, anti-p85 subunit of PI3K, or anti-PKC-z
antibody. The other two-thirds of the immunoprecipitate was used
for kinase assays. For p70S6 kinase activity assays, the reaction was
initiated by [g-32P]ATP (3000 Ci/mmol, Perkin-Elmer Life Sciences)
as described previously (Eguchi et al., 1999). PKC-z activity assays
were performed as described (Wali et al., 2003) by the initiation of
the reaction with 10 mCi [g-32P]ATP (3000 Ci/mmol, Perkin-
Elmer Life Sciences) and 10 mg MBP in a total reaction volume of
50 ml. The g-32P-labeled product from either the p70S6 kinase
activity assay or the PKC-z activity assay was measured in a
Beckman LS 6000 liquid scintillation counter. Assays for the activity
of ERK were performed as described previously (Wang et al., 2001a).
The g-32P-labeled MBP was treated with boiled Laemmli buffer and
applied to a 12% SDS-PAGE mini-gel. PI3K activity was measured as
described (Wang et al., 2002b). The phosphorylated products from
either ERK activity or PI3K activity analysis were visualized by
autoradiography with Kodak X-Omat film, developed at 801C
overnight, and quantified by a Storm 800 Fluorescence Phos-
phorImager. All kinase activity assays were performed three times
in triplicate.
BrdU incorporation assays
BrdU incorporation assays were performed to monitor the effect of
modulation of GM3 expression on cell proliferation. SCC12 cells
were treated with or without either sense or antisense oligodeoxy-
nucleotides to both GM2/GD2 synthase and GD3 synthase, and with
or without 140mM purified GM3 or its vehicle, DMSO. These treated
or untreated SCC12 cells were synchronized in the G0 phase by
serum and growth factor starvation for 6 hours in the presence
or absence of either oligodeoxynucleotides or purified GM3. Cells
were then trypsinized, detached, and plated onto 96-well plates
(104 cells/well). After incubation in serum- and growth factor-free
medium to further synchronize cells for 12–18 hours, 10 nM uPA and
10 mM BrdU were added for another 24 hours. BrdU incorporation
was stopped by washing cells with cold PBS (pH 7.6). Cells were
then fixed, stained and the absorbance was read at A450 nm as
per the manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN).
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